Drug Profile
DG 17
Alternative Names: NAR DG-35Latest Information Update: 10 Nov 2021
Price :
$50
*
At a glance
- Originator Narhex Australia Pty Ltd
- Class Antivirals; Small molecules
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 14 Oct 2021 Discontinued - Phase-I for HIV infections in Australia (PO) (Narhex Australia website, October 2021).
- 14 Oct 2021 Discontinued - Phase-II for HIV infections in Brazil (PO) (Narhex Australia website, October 2021)
- 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections in Australia (PO)